Exclusive Life Science Feature
AstraZeneca Translates
"Winning With
Science"
From Words To Action
By Wayne Koberstein, executive editor
A
majority of the recent press on AstraZeneca
has tried to criticize the company over its
late-phase failures with once-promising
products in development. But in many
ways the fates of those products were sealed years
ago — long before the large-scale human trials were
completed and their results tallied. Yet the choices
made now and the company's current moves to
reverse its fortunes will neither face their ultimate
test nor show their true worth for many years to
come. So how do we judge their chances of success
before then?
September 2013
LifeScienceLeader.com
31